Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW.

J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345.

2.

Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study.

Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A.

Am J Psychiatry. 2015 Jan;172(1):52-8. doi: 10.1176/appi.ajp.2014.13060787. Epub 2014 Oct 31.

PMID:
25157964
3.

Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.

Muscatello MR, Pandolfo G, Micò U, Lamberti Castronuovo E, Abenavoli E, Scimeca G, Spina E, Zoccali R, Bruno A.

J Clin Psychopharmacol. 2014 Feb;34(1):129-33. doi: 10.1097/JCP.0000000000000042.

PMID:
24145221
4.

Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia.

Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S.

Eur Psychiatry. 2014 Jan;29(1):1-10. doi: 10.1016/j.eurpsy.2013.08.001. Epub 2013 Oct 9. Review.

PMID:
24119631
5.

Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.

Lin CC, Chiu HJ, Chen JY, Liou YJ, Wang YC, Chen TT, Bai YM.

J Clin Psychopharmacol. 2013 Apr;33(2):211-4. doi: 10.1097/JCP.0b013e31828700c7.

PMID:
23422395
6.

Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial.

Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, Richards S, Javaid N.

J Clin Psychopharmacol. 2012 Feb;32(1):95-9. doi: 10.1097/JCP.0b013e31823f913e.

PMID:
22198452
7.

A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine.

de Jesus DR, Gil A, Barbosa L, Lobato MI, Magalhães PV, Favalli GP, Marcolin MA, Daskalakis ZJ, Belmonte-de-Abreu Pda S.

Psychiatry Res. 2011 Jul 30;188(2):203-7. doi: 10.1016/j.psychres.2010.11.022. Epub 2010 Dec 24.

PMID:
21186062
8.

Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects.

Hahn MK, Remington G, Bois D, Cohn T.

J Clin Psychopharmacol. 2010 Dec;30(6):706-10.

PMID:
21105286
9.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR.

Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.

PMID:
20399340
10.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
11.

Aripiprazole in treatment-refractory schizophrenia.

Hsu WY, Lee CI, Chiu NY, Kahn DA.

J Psychiatr Pract. 2009 May;15(3):221-6. doi: 10.1097/01.pra.0000351883.75754.45.

PMID:
19461396
12.

Practical issues with amisulpride in the management of patients with schizophrenia.

Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.

Clin Drug Investig. 2008;28(8):465-77. Review.

PMID:
18598092
13.

A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia.

Doruk A, Uzun O, Ozşahin A.

Int Clin Psychopharmacol. 2008 Jul;23(4):223-7. doi: 10.1097/YIC.0b013e3282fcff2f.

PMID:
18545061
14.
15.

Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.

Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS.

J Clin Psychiatry. 2008 May;69(5):720-31.

PMID:
18370574
16.

Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.

Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N.

J Am Acad Child Adolesc Psychiatry. 2007 Oct;46(10):1349-56.

PMID:
17885577
17.

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.

Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM.

Biol Psychiatry. 2008 Mar 1;63(5):524-9. Epub 2007 Jul 25.

PMID:
17651705
18.

Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1330-6. Epub 2007 Jun 12.

PMID:
17618026
19.

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study.

Zoccali R, Muscatello MR, Bruno A, Cambria R, Micò U, Spina E, Meduri M.

Schizophr Res. 2007 Jul;93(1-3):109-16. Epub 2007 Mar 26.

PMID:
17383857
20.

Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment.

Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, Kennedy JL.

Eur Neuropsychopharmacol. 2006 May;16(4):248-59. Epub 2005 Nov 8.

PMID:
16278074

Supplemental Content

Loading ...
Support Center